These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20134113)

  • 1. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.
    Yoshida A; Fujino T; Maruyama S; Ito Y; Taki Y; Yamada S
    J Pharmacol Sci; 2010; 112(2):142-50. PubMed ID: 20134113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.
    Yamada S; Kuraoka S; Osano A; Ito Y
    Int Neurourol J; 2012 Sep; 16(3):107-15. PubMed ID: 23094215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
    Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
    J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
    Maruyama S; Hasuike N; Suzuki K; Yamada S
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
    Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
    J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
    Oki T; Sato S; Miyata K; Yamada S
    Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
    Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
    Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscarinic receptors in the bladder: from basic research to therapeutics.
    Hegde SS
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
    Sinha S; Gupta S; Malhotra S; Krishna NS; Meru AV; Babu V; Bansal V; Garg M; Kumar N; Chugh A; Ray A
    Br J Pharmacol; 2010 Jul; 160(5):1119-27. PubMed ID: 20590605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
    Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
    J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.